InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,648.40
(
1.01%
)
US TECH 100
19,050.80
(
0.00%
)
Dow Jones
41,563.08
(
0.55%
)
Brent Oil
76.84
(
-0.46%
)
Bitcoin
59,108.09
(
-0.02%
)
Post# of 253010
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120354
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 76008

Wednesday, 04/15/2009 4:12:12 PM

Wednesday, April 15, 2009 4:12:12 PM

Post# of 253010
ABT was down 5% today (a big move for a Big Pharma) because of the shortfall in 1Q09 Humira sales ($1.02B) relative to 4Q08 ($1.35B). The Humira drop-off was entirely in the US, where quarter-over-quarter sales declined from $751M to $410M. Ex-US, Humira sales increased quarter-over-quarter from $600M to $614M.

The market evidently isn’t buying ABT’s explanation that much of the QoQ decline in US Humira sales was due to inventory destocking. Yet the company’s guidance for full-year growth in worldwide Humira sales is still 15-20% (down from 25%), and that ain’t bad.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up